Effect of raloxifene and atorvastatin in atherosclerotic process in ovariectomized rats

Journal of Obstetrics and Gynaecology Research

Volumn 39, Issue 1, 2013, Pages 229-236

  Demir, Bilge Çetinkaya ^a   Uyar, Yildiz ^b   Ozbilgin, Kemal ^c   Köse, Can ^c  

^a ULUDAG UNIVERSITY   (Turkey)

^b Deparment of Obstetrics and Gynecology   (Turkey)

^c CELAL BAYAR UNIVERSITY   (Turkey)

Author keywords

Estrogen; Menopause; Rat; Selective estrogen receptor modulator; Statin

Indexed keywords

ATORVASTATIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; MONOCYTE CHEMOTACTIC PROTEIN 1; RALOXIFENE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM; FEMALE; IMMUNOHISTOCHEMISTRY; NONHUMAN; OVARIECTOMY; RAT; TREATMENT DURATION;

ANIMALS; AORTA, THORACIC; ATHEROSCLEROSIS; CHEMOKINE CCL2; ENDOTHELIUM, VASCULAR; ESTROGEN ANTAGONISTS; FEMALE; HEPTANOIC ACIDS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; NITRIC OXIDE SYNTHASE TYPE II; NITRIC OXIDE SYNTHASE TYPE III; OVARIECTOMY; PYRROLES; RALOXIFENE; RATS; RATS, WISTAR; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84875694262     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2012.01969.x     Document Type: Article

References (40)

1. Ertungeal E. Menopoz ve osteoporoz tarihçesi (The history of menopause and osteoporosis). In: Ertungealp E, Seyisoǧ lu H (eds). Menopoz ve Osteoporoz. Istanbul: Ulusal Menopoz ve Osteoporoz Dernegi, 2000; 2.
2. Speroff L, Glass RH, Kase NG. Menopause and the perimenopausal transition. In: Mitchell C (ed.). Clinical Gynecologic Endocrinology and Infertility, 6th edn. Baltimore: Lippincott Williams and Wilkins, 1999; 672.
3. Wilson PWF. The endothelium in atherothrombosis. In: Wilson Peter WF (ed.). Atlas of Atherosclerosis Risk Factors and Treatment, 2nd edn. Philadelphia, PA: Current Medicine Group, 2000; 25-30. ISBN: 1573401374.
4. Libby P. Inflammation in atherosclerosis. Nature 2002; 420: 868-874.
5. Teplyakov AI. Endothelin-1 involved in systemic cytokine network inflammatory response at atherosclerosis. J Cardiovasc Pharmacol 2004; 44: 274-275.
6. Zenovich AG, Taylor DA. Atherosclerosis as a disease of failed endogenous repair. Front Biosci 2008; 13: 3621-3636.
7. Lerman A, Edwards BS, Hallett JW, Heublein DM, Sandberg SM, Burnett JC. Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. N Engl J Med 1991; 325: 997-901.
8. McCarron RM, Wang L, Stanimirovic DB, Spatz M. Endothelin induction of adhesion molecule expression on human brain microvascular endothelial cells. Neurosci Lett 1993; 156: 31-34.
9. Halim A, Kanayama N, el Maradny E, Maehara K, Terao T. Coagulation in vivo microcirculation and in vitro caused by endothelin-1. Thromb Res 1993; 72: 203-209.
10. Mathew V, Hashadi D, Lerman A. The role of endothelin in coronary atherosclerosis. Mayo Clin Proc 1996; 71: 769-777.
11. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43: 109-142.
12. Kibbe M, Billiar T, Tzeng E. Inducible nitric oxide synthase and vascular injury. Cardiovasc Res 1999; 43: 650-657.
13. Hansson G, Geng YJ, Holm J, Hardhammar P,Wennmalm A, Jennische E. Arterial smooth muscle cells express nitric oxide synthase in response to endothelial injury. J Exp Med 1994; 180: 737-738.
14. Sites C, Toth M, Cushman M et al. Menopause-related differences in inflammation markers and their relationship to body fat distribution and insulin-stimulated glucose disposal. Fertil Steril 2002; 77: 128-135.
15. Almuti K, Rimawi R, Spevack D. Effects of statin beyond lipid lowering: Potential for clinical benefits. Int J Cardiol 2006; 109: 7-15.
16. Tee MK, Rogatsky I, Tzagarakis-Foster C et al. Estradiol and selective estrogen receptor modulators differentially regulate target genes with estrogen receptors a and b. Mol Biol Cell 2004; 15: 1262-1272.
17. Bjarnason N, Haarbo J, Byrjalsen I, Kauffman R, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized cholesterol-fed rabbits. Circulation 1997; 96: 1964-1969.
18. Wong C, Yao X, Au C, Tsang S, Fung K, Laher I. Raloxifene prevents endothelial function in aging ovariectomized female rats. Vascul Pharmacol 2005; 44: 290-298.
19. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch J, Ahlbory K. Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 2002; 105: 2083-2091.
20. Leung F, Yung L, Leung H, Au C, Yao X, Vanhoutte P. Therapeutic concentrations of raloxifene augments nitric oxidependent relaxation in porcine coronary artery. Br J Pharmacol 2007; 152: 223-229.
21. Yada-Hashimoto N, Yukihiro N, Ohmichi M. Estrogen and raloxifen inhibit the monocytic chemoattractant protein-1-induced migration of human monocytic cells via nongenomic estrogen receptor alfa. Menapause 2006; 13: 935-941.
22. Huber C, Collishaw S, Mosley J, Reeve J, Noble B. Selective estrogen receptor modulator inhibits osteocyte apoptosis during abrupt estrogen withdrawal: Implications for bone quality maintenance. Calcif Tissue Int 2007; 81: 139-144.
23. Lindner V, Kim S, Karas R. Increased expression of estrogen receptor-beta mRNA in male blood vessels after vascular injury. Circ Res 1998; 83: 224-229.
24. Pare G, Krust A, Karas R. Estrogen receptor-Alpha mediates the protective effects of estrogen against vascular injury. Circ Res 2002; 90: 1087-1092.
25. Okano H, Jayachandran M, Yoshikawa A, Miller M. Differential effects of chronic treatment with estrogen receptor ligands on regulation of nitric oxide synthase in porcine aortic endothelial cells. Cardiovasc Pharmacol 2006; 47: 621-628.
26. Paige L, Christensen D, Gron J. Estrogen receptor (ER) modulators each induce distinct conformational changes in ER alpha and ER beta. Proc Natl Acad Sci USA 1999; 96: 3999-3904.
27. Qiao X, McConnell KR, Khalil RA. Sex steroids and vascular responses in hypertension and aging. Gend Med 2008; 5 (Suppl A): S46-S64.
28. Lefer D, Scalia R, Jones S et al. HMG-CoA reductase inhibition protects the diabetic myocardium from ischemiareperfusion injury. FASEB J 2001; 15: 1454-1456.
29. Laufs U, Liao J. Post-Transcriptional regulation of endothelial nitric oxide synthase mRNA stability by rhoGTPase. J Biol Chem 1998; 273: 24266-24272.
30. Laufs U, Fata VL, Plutzky J, Liao J. Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors. Circulation 1998; 97: 1129-1135.
31. Akishita M, Ouchi Y, Miyoshi H. Estrogen inhibits endothelin-1 production and c-fos gene expression in rat aorta. Atherosclerosis 1996; 125: 27-38.
32. Pinna C, Bolego C, Sanvito P et al. Raloxifene elicits combined rapid vasorelaxation and long-Term anti-inflammatory actions in rat aorta. J Pharmacol Exp Ther 2006; 319: 1444-1451.
33. Luoma J, Yla-Herttuala S. Expression of inducible nitric oxide synthase in macrophages and smooth muscle cells in various types of human atherosclerotic lesions. Virchows Arch 1999; 434: 561-568.
34. David F, Carvalho M, Cobra A. Ovarian hormones modulate endothelin-1 vascular reactivity and mRNA expression in DOCA-salt hypertensive rats. Hypertension 2001; 38: 692-696.
35. Christodoulakos G, Panoulis C, Kouskouni E. Effects of estrogen-progestin and raloxifene therapy on nitric oxide, prostacyclin and endotelin-1 synthesis. Gynecol Endocrinol 2002; 16: 9-17.
36. Saitta A, Altavilla D, Cucinotta D, Morabito N, Firisina N, Corrado F. Randomized, double-blind, placebo-controlled study on effects of raloxifene and hormone replacement therapy on plasma NO concentrations, endothelin-1 levels, and endothelium-dependent vasodilation in postmenopausal women. Arterioscler Thromb Vasc Biol 2001; 21: 1512-1519.
37. Vovelgang T, Mooren M, Mijatovic V, Kenemans P. Emerging selective estrogen receptor modulators. Drugs 2006; 66: 191-221.
38. Hernandez-Perera O, Perez-Sala D, Navarro-Antolin J et al. Effects of the 3-hydroxy-3-methylglutaryl-coa reductase inhibitors, atorvastatin and simvastatin, on the expression of endothelin-1 and endothelial nitric oxide synthase in vascular endothelial cells. J Clin Invest 1998; 101: 2711-2719.
39. Hernandez-Perera O, Perez-Sala D, Soria E, Lamas S. Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells. Circ Res 2000; 87: 616-622.
40. Seli E, Selam B, Mor G, Kayisli UA, Pehlivan T, Arici A. Estradiol regulates monocyte chemotactic protein-1 in human coronary artery smooth muscle cells: A mechanism for its antiatherogenic effect. Menopause 2001; 8: 296-201.